Mobble
Health · Cancer research · published 2026-08-26 · via Endpoints News

FDA clears Revolution Medicines' daraxonrasib for pancreatic cancer

The FDA has approved Revolution Medicines' daraxonrasib for second-line treatment of pancreatic cancer. The drug is seen as a significant advance for a disease with poor prognosis. Approval is expected to change treatment options for patients.

Read the full article at Endpoints News →
Related stories
Gene therapy approval and Regeneron's rare disease win headline biotech updates · Drug development
Bristol's new myeloma drug wins FDA approval, opening a new treatment category · Cancer research
Today's pharma briefing: Legal clash over drug testing and a new cancer therapy · Cancer research
Bispecific Antibody Regimen Approved for HER2-Positive Upper GI Cancers · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “FDA approves Revolution Medicines' pancreatic cancer drug.” Browse more stories.